1. School of Physiology, Pharmacology and Neuroscience, Faculty of Biomedical Sciences, University of Bristol, Bristol, United Kingdom;
2. Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Mölndal, Sweden; and
3. School of Clinical Sciences, Faculty of Health Sciences, University of Bristol, Bristol, United Kingdom